日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Population-Level Risks for HIV Mortality During the COVID-19 Pandemic in the United States by Demographic Characteristics and Medicaid Access, 2020‒2021

2020-2021年美国COVID-19大流行期间,按人口特征和医疗补助计划覆盖情况划分的HIV死亡人群风险

Purcell, Donrie; Duffus, Wayne A; Standifer, Maisha; Mayberry, Robert; Hutchins, Sonja S

Disparities in HIV Care: A Rural-Urban Analysis of Healthcare Access and Treatment Adherence in Georgia

艾滋病治疗方面的差异:佐治亚州城乡医疗保健服务获取和治疗依从性分析

Purcell, Donrie J; Standifer, Maisha; Martin, Evan; Rivera, Monica; Hopkins, Jammie

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and

2025 年生物分析最新问题白皮书:生物标志物校准品和稳定性;核素标记免疫球蛋白结合免疫球蛋白 (NULISA) 的评估;神经丝和自身抗体生物标志物检测;消除 IgM 干扰;酶联免疫斑点 (ELISpot) 和荧光斑点 (FluoroSpot) 最佳实践;模块化高清流式细胞术;单细胞分析成像流式细胞术(第二部分 A - 关于生物标志物发现、开发、验证和监管审批、配体结合分析 (LBA) 和基于细胞的分析 (CBA) 的建议;第二部分 B - 监管机构对生物标志物、体外诊断/伴随诊断 (IVD/CDx) 的意见)

Hersey, Sarah; McGuire, Kristina; Kholmanskikh, Olga; Bivi, Nicoletta; Bandukwala, Abbas; Gong, Binsheng; Irwin, Chad; Ray, Soma; Gunsior, Michele; Avanesov, Andrei; Baker, Brian; Bond, Sarah; Braun, Alexander; Buoninfante, Alessandra; Dessy, Francis; Fang, Xiaodong; Garofolo, Fabio; Gomme, Emily; Hays, Amanda; King, Lindsay; Mayer, Christian; McGregor, Jessica; McHenry, Melis; Nowocin, Anna; Rubel, Carrie; Sanderink, Gerard; Scott, Bradley; Scully, Ingrid; Seyda, Agnes; Stoop, Jeroen; Tang, Huaping; Neto, Joao Tavares; Walravens, Karl; Wang, Kai; Wassmer, Sarah; Xiao, Wenming; Zhu, Liang; Zoghbi, Jad; Brockus, Catherine; Petit-Frere, Corinne; Coble, Kelly; Fischer, Sally; Yearwood, Graham; Cao, Liching; Dysinger, Mark; Grimaldi, Christine; Jiang, Yong; Joyce, Alison; Kerridge, Claire; Lu, Kun; McCush, Fred; Nolan, Katrina; Connor, Ellen O'; Palmer, Rachel; Reese, Kimberly; Stubenrauch, Kay-Gunnar; Verch, Thorsten; Beaver, Christopher; Mendez, Luis; Decman, Vilma; Bhavaraju, Kamala; Huleatt, James; Trampont, Paul C; Eck, Steven; Goihberg, Polina; Alcaide, Enrique Gomez; Hedrick, Michael Nathan; Jalah, Rashmi; McGrath, Shannon; Ogorman, William; Prior, Sandra; Sehra, Sarita; Shaik, Saleem; Standifer, Nathan; Stevens, Chad; Stevens, Erin; Sun, Yongliang Steve

2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA (PART 2A - Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation)

2024 年生物分析最新议题白皮书:美国实验室自建检测 (LDT) 和欧盟体外诊断医疗器械法规 (IVDR) 的影响;高参数流式细胞术的 AI/ML;Olink 技术的崛起;腺相关病毒 (AAV) 基因疗法的伴随诊断 (CDx);多平台整合生物分析;超灵敏 ADA/NAb 配体结合分析 (LBA)(第二部分 A - 生物标志物、体外诊断/伴随诊断检测 (BAV)、细胞检测 (CBA) 和配体结合分析 (LBA) 的高级策略建议;第二部分 B - 监管机构对生物标志物、体外诊断/伴随诊断和生物标志物检测验证的意见)

Bivi, Nicoletta; Graham, Danielle; Joglekar, Laura; McGuire, Kristina; Stoop, Jeroen; Zoghbi, Jad; Baker, Brian; Bandukwala, Abbas; Bond, Sarah; Buoninfante, Alessandra; Chen, Jeff; Dysinger, Mark; Engelbergs, Jörg; Fiscella, Michele; Garofolo, Fabio; Hopper, Shirley; Jones, Barry; King, Lindsay; Murphy, Rocio; Palmer, Rachel; Sanderink, Gerard; Seyda, Agnes; Tang, Huaping; Van Tuyl, Andrea; Wagner, Leslie; Walravens, Karl; Wang, Kai; Zander, Hilke; Zhu, Liang; Li, Ming; Lin, Yi-Dong; Natalia, Mahwish; Standifer, Nathan; Eck, Steven; Goihberg, Polina; Grugan, Katharine; Hedrick, Michael Nathan; Hopkins, Greg; Kar, Sumit; Keller, Steve; McGrath, Shannon; O'Gorman, Bill; Stevens, Chad; Stevens, Erin; Terszowski, Grzegorz; Trampont, Paul C; Yao, Shuyu; Joyce, Alison; Kumar, Seema; Owen, Carolina; Pine, Samuel; Yearwood, Graham; Cao, Liching; Clausen, Valerie; Coble, Kelly; Culbert, Andria; Gupta, Shalini; Hughes, Richard; Liu, Susana; Lu, Kun; Martello, Rita; Reese, Kimberly J; Stubenrauch, Kay-Gunnar; Wen, Yi

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境增强癌症检查点免疫疗法的疗效。

Elizabeth L Hardaker # ,Emilio Sanseviero # ,Ankur Karmokar # ,Devon Taylor # ,Marta Milo ,Chrysis Michaloglou ,Adina Hughes ,Mimi Mai ,Matthew King ,Anisha Solanki ,Lukasz Magiera ,Ricardo Miragaia ,Gozde Kar ,Nathan Standifer ,Michael Surace ,Shaan Gill ,Alison Peter ,Sara Talbot ,Sehmus Tohumeken ,Henderson Fryer ,Ali Mostafa ,Kathy Mulgrew ,Carolyn Lam ,Scott Hoffmann ,Daniel Sutton ,Larissa Carnevalli ,Fernando J Calero-Nieto ,Gemma N Jones ,Andrew J Pierce ,Zena Wilson ,David Campbell ,Lynet Nyoni ,Carla P Martins ,Tamara Baker ,Gilberto Serrano de Almeida ,Zainab Ramlaoui ,Abdel Bidar ,Benjamin Phillips ,Joseph Boland ,Sonia Iyer ,J Carl Barrett ,Arsene-Bienvenu Loembé ,Serge Y Fuchs ,Umamaheswar Duvvuri ,Pei-Jen Lou ,Melonie A Nance ,Carlos Alberto Gomez Roca ,Elaine Cadogan ,Susan E Critichlow ,Steven Fawell ,Mark Cobbold ,Emma Dean ,Viia Valge-Archer ,Alan Lau ,Dmitry I Gabrilovich ,Simon T Barry

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

莫那珠单抗联合度伐利尤单抗治疗晚期实体瘤患者的1/2期研究

Patel, Sandip P; Alonso-Gordoa, Teresa; Banerjee, Susana; Wang, Ding; Naidoo, Jarushka; Standifer, Nathan E; Palmer, Doug C; Cheng, Lin-Yang; Kourtesis, Panagiotis; Ascierto, Maria L; Das, Mayukh; Diamond, Jennifer R; Hellmann, Matthew D; Carneiro, Benedito A

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

TPST-1120(一种 PPARα 抑制剂)作为单药疗法或与纳武利尤单抗联合疗法治疗晚期实体瘤患者的首次人体 I 期试验

Yarchoan, Mark; Powderly, John D; Bastos, Bruno R; Karasic, Thomas B; Crysler, Oxana V; Munster, Pamela N; McKean, Meredith A; Emens, Leisha A; Saenger, Yvonne M; Ged, Yasser; Stagg, Robert; Smith, Steven; Whiting, Chan C; Moon, Anne; Prasit, Peppi; Jenkins, Yonchu; Standifer, Nathan; Dubensky, Thomas W; Whiting, Sam H; Ulahannan, Susanna V

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors

CD40激动剂MEDI5083联合度伐利尤单抗治疗晚期实体瘤患者的I期研究

Tran, Ben; Voskoboynik, Mark; Bendell, Johanna; Gutierrez, Martin; Lemech, Charlotte; Day, Daphne; Frentzas, Sophia; Garrido-Laguna, Ignacio; Standifer, Nathan; Wang, Fujun; Ferte, Charles; Wang, Yue; Das, Mayukh; Carneiro, Benedito A

Traumatic Brain Injury Induces Nociceptin/Orphanin FQ and Nociceptin Opioid Peptide Receptor Expression within 24 Hours

创伤性脑损伤在 24 小时内诱导 Nociceptin/Orphanin FQ 和 Nociceptin 阿片肽受体表达

Omar N Al Yacoub, Yong Zhang, Panini S Patankar, Kelly M Standifer

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受曲美利单抗单药治疗或联合度伐利尤单抗治疗的暴露-反应分析

Song, Xuyang; Kelley, Robin Kate; Khan, Anis A; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F; Abou-Alfa, Ghassan K